GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyell Immunopharma Inc (NAS:LYEL) » Definitions » PS Ratio

Lyell Immunopharma (Lyell Immunopharma) PS Ratio : (As of May. 01, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lyell Immunopharma PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lyell Immunopharma's share price is $2.33. Lyell Immunopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Hence, Lyell Immunopharma's PS Ratio for today is .

The historical rank and industry rank for Lyell Immunopharma's PS Ratio or its related term are showing as below:

LYEL' s PS Ratio Range Over the Past 10 Years
Min: 5.84   Med: 26.16   Max: 2423.44
Current: 2377.52

During the past 5 years, Lyell Immunopharma's highest PS Ratio was 2423.44. The lowest was 5.84. And the median was 26.16.

LYEL's PS Ratio is ranked worse than
97.79% of 996 companies
in the Biotechnology industry
Industry Median: 9.095 vs LYEL: 2377.52

Lyell Immunopharma's Revenue per Sharefor the three months ended in Dec. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

Warning Sign:

Lyell Immunopharma Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Lyell Immunopharma was -99.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was -70.00% per year.

During the past 5 years, Lyell Immunopharma's highest 3-Year average Revenue per Share Growth Rate was 385.40% per year. The lowest was -70.00% per year. And the median was 157.70% per year.

Back to Basics: PS Ratio


Lyell Immunopharma PS Ratio Historical Data

The historical data trend for Lyell Immunopharma's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyell Immunopharma PS Ratio Chart

Lyell Immunopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
- - 99.23 10.12 1,940.00

Lyell Immunopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.12 6.96 16.39 7.58 -

Competitive Comparison of Lyell Immunopharma's PS Ratio

For the Biotechnology subindustry, Lyell Immunopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyell Immunopharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where Lyell Immunopharma's PS Ratio falls into.



Lyell Immunopharma PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Lyell Immunopharma's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=2.33/0
=

Lyell Immunopharma's Share Price of today is $2.33.
Lyell Immunopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Lyell Immunopharma  (NAS:LYEL) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Lyell Immunopharma PS Ratio Related Terms

Thank you for viewing the detailed overview of Lyell Immunopharma's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyell Immunopharma (Lyell Immunopharma) Business Description

Traded in Other Exchanges
N/A
Address
201 Haskins Way, South San Francisco, CA, USA, 94080
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).
Executives
Richard Klausner director, officer: Executive Chairman 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Matthew Lang officer: Chief Business Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Rahsaan Thompson officer: Chief Legal Officer 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Tina M. Albertson officer: Chief Medical Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Gary K. Lee officer: Chief Scientific Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Arch Venture Fund Ix Overage, L.p. 10 percent owner 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Elizabeth Homans director, officer: Chief Executive Officer C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Stephen J. Hill officer: Chief Technical Ops. Officer C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Charles W. Newton officer: Chief Financial Officer 46 FREDRICK AVENUE, ATHERTON CA 94027
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
William Jl Rieflin director NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Arch Venture Partners Ix, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631